Are complex karyotypes reliable prognostic markers for CLL?
PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)?
How far are we from a cure for CLL?
Present issues in treating patients with relapsed/refractory CLL
Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL